![[Bio USA] GI Innovation unveils next-gen immunotherapy pipeline](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F18%2Fnews-p.v1.20250618.d08a9f94aea74f3da95329681a945806_T1.jpg&w=3840&q=100)
[Bio USA] GI Innovation unveils next-gen immunotherapy pipeline
Leading the presentation was Yun Nari, head of GI Innovation's clinical strategy, who introduced the company's new drug development pipeline and global business roadmap. A licensed pharmacist, Yun joined the company's board of directors in March and is expected to play a pivotal role in accelerating clinical decision-making, an essential function in GI Innovation's core business of clinical-stage drug development.
A key highlight was the unveiling of GI-128, a novel immuno-oncology candidate that leverages macrophage engagement, an emerging target in next-generation cancer therapies. The company also spotlighted its trispecific antibody pipeline, designed to surpass the current generation of aPD-(L)1/VEGF bispecific antibodies, which are gaining significant traction in the global oncology space.
'This year's Bio USA is a premier platform that brings together leading global investors and pharmaceutical companies,' said Jang Myoung-ho, CEO and founder of GI Innovation. 'It presented the perfect opportunity to demonstrate the competitiveness of our pipeline and global expansion strategy. We plan to actively explore a variety of partnership opportunities, including technology licensing, co-development deals and strategic investments.'
Meanwhile, the growing interest in aPD-(L)1/VEGF bispecific antibodies in the immuno-oncology sector has led to a surge in high-value deals. Bristol Myers Squibb recently entered into a licensing agreement with German biotech firm BioNTech, paying an upfront sum of approximately $1.5 billion, with the total deal valued at around $11.1 billion. Likewise, Merck & Co. signed a deal last year with China-based LaNova Medicines, worth $588 million upfront and up to $2.7 billion in milestone payments.
Building on this trend, GI Innovation's trispecific antibody platform integrates the company's proprietary aPD-L1 antibody, a VEGF antibody and a macrophage engager into a single molecule. The design aims to overcome the therapeutic limitations of bispecific antibodies by stimulating a more robust immune response within the tumor microenvironment, the company explained.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
8 hours ago
- Korea Herald
Lee to meet Bill Gates to discuss global health issues, collaboration
President Lee Jae Myung plans to meet Bill Gates, chair of the Gates Foundation and Microsoft Corp. co-founder, in Seoul on Thursday, the presidential office said Wednesday. Gates, who has spearheaded initiatives on climate change, poverty reduction and global health through the foundation, is visiting South Korea to reportedly explore cooperation with Korean pharmaceutical companies on a vaccine supply project for low-income countries. During the meeting at the presidential office, the two are expected to discuss global health issues and potential collaboration in the sector, according to officials. (Yonhap)
Korea Herald
13 hours ago
- Korea Herald
HD KSOE acquires Doosan Vina at W290b
Shipbuilding giant looks to bolster production of independent tanks to maximize profitability of eco-friendly vessels HD Korea Shipbuilding & Offshore Engineering, an intermediary holding firm of Korean shipbuilding conglomerate HD Hyundai, said Wednesday that it has signed a deal with Doosan Enerbility to acquire the latter's Vietnamese company, Doosan Vina, in order to expand its lineup of eco-friendly vessels. According to HD KSOE, it agreed to buy out Doosan Enerbility's 100 percent stake in Doosan Vina at a price of 290 billion won ($207 million). Doosan Enerbility said it will utilize the 290 billion won it secures from the deal to expand facilities in core businesses, such as small modular reactors and gas turbines, which are seeing rapid growth in demand amid the increasing need for energy and carbon reduction across the globe. Doosan Vina, which was established in 2006 in the Dung Quat Economic Zone of Quang Ngai Province, Central Vietnam, has manufactured boilers for thermal power plants, port cranes and modules for liquefied natural gas plants. HD KSOE plans to carry on the existing business of Doosan Vina while utilizing the newly acquired site as a regional foothold to build independent tanks and port cranes for the Asian region. An independent tank is a key component in eco-friendly vessels such as LNG-fueled vessels, liquefied petroleum gas carriers, ammonia carriers and liquefied carbon dioxide carriers. 'This deal was able to be finalized as it fulfills the interests of both companies, backed by the government's cooperation and support,' said an HD KSOE official. 'As we have expanded our production capacity of eco-friendly equipment, we plan to maximize profitability by bolstering our lineup of globally competitive eco-friendly vessels."
Korea Herald
13 hours ago
- Korea Herald
BlueOval SK rolls out 1st EV battery product
SK On-Ford joint battery venture in Kentucky seeks customer diversification amid lagging EV growth BlueOval SK, a 50:50 joint venture between Korean battery maker SK On and American automaker Ford, has finally begun commercial production of electric vehicle batteries at its first Kentucky plant amid the prolonged stagnation of the EV market growth. According to BlueOval SK on Tuesday, its first-ever battery to be delivered to Ford rolled off the assembly line at the Kentucky 1 factory in Glendale. The batteries from this production will power the American automaker's electric pickup truck, the F-150 Lightning. 'We are proud to build batteries at our Kentucky 1 facility that will power next-generation electric vehicles,' BlueOval SK CEO Michael Adams said. 'The start of production is a significant milestone that strengthens our position in the electric vehicle battery market.' BlueOval SK added that the Kentucky 1 plant will also produce batteries for Ford's current E-Transit electric van. SK On and Ford joined hands to set up BlueOval SK in 2022 as they announced a $11.4 billion investment to build three battery production facilities: two in Glendale, Kentucky and one in Stanton, Tennessee. 'Today, Kentucky marks a historic milestone four years in the making as production officially begins at two of the largest battery plants in the world, set to deliver EV batteries that will transform the automotive industry and the future of our commonwealth,' said Kentucky Governor Andrew Beshear. 'This remains the single largest investment in the history of our state, and it sparked a surge of new investment and job announcements that placed Kentucky at the center of EV-related innovation. I am grateful to Ford and SK On leaders for believing in Kentucky and our workforce.' The joint venture's first commercial production has been delayed due to the EV market's slower-than-anticipated growth rate over the last few years. Ford announced earlier this month that it will delay the launch of two new EVs — next-generation models of the F-150 Lightning and E-Transit — to 2028 but instead shift focus to smaller, more affordable cars to launch a midsize, four-door electric pickup in 2027. With the stalling EV demand, Adams, CEO of BlueOval SK, said in an interview with Bloomberg that both SK On and Ford are looking for opportunities for new business and securing new clients is 'fairly high.' There have been rumors that BlueOval SK was nearing a contract to sell batteries to Nissan, but no confirmations were made.
